Three late-breaking reports will be part of AbbVie's 60 research presentations on skin diseases.
Three late-breaking reports will be part of AbbVie's 60 research presentations on skin diseases. Stock Titan
Covered in this story
Analyst targets on AbbVie
- Citi: $244 → $260 by Jul 2027 · Neutral via GuruFocus
- UBS: $248 → $260 by Jul 2027 · Neutral via GuruFocus
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ABBV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on AbbVie →Dalsna Finance is currently tracking 50 stories mentioning AbbVie, the earliest published 15 May 2026.
Summary aggregated from Stock Titan's public RSS feed. The full reporting belongs to Stock Titan — please read it on their site.